"Over the past decade, we have evaluated numerous therapeutic approaches for the treatment of lethal viruses, such as Ebola," said co-author Dr. Lisa E. Hensley of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). "None of them have conferred complete protection to Ebola virus-infected primates—until now."
Using particles called small interfering RNAs (siRNAs), the authors targeted a protein (called the L protein) that is essential for Ebola virus replication. RNA inhibitors, as they are commonly called, are based on a natural gene silencing mechanism used by all cells, and RNAi therapeutics rely on a delivery technology to be effective.
Lipid nanoparticles (LNPs) are the most widely used siRNA delivery approaches. In this study, the research team used a proprietary technology called SNALP, or stable nucleic acid-lipid particles, to deliver the therapeutics to disease sites in animal models infected with the Zaire strain of Ebola virus (ZEBOV).
A group of three rhesus macaques was given anti-ZEBOV siRNAs intravenously, 30 minutes after exposure to the virus, and again on days 1, 3, and 5. A second group of four macaques was given the treatment after 30 minutes, and on days 1, 2, 3, 4, 5, and 6, after challenge with ZEBOV.
Two of the three animals in the first group (which received four post-exposure treatments) were protected from lethal ZEBOV infection and survived. All four of the monkeys given seven post-exposure treatments were protected. The treatment regimen in the second study was well tolerated, with minor changes in liver enzymes that might have been related to viral infection.
The study represents the first demonstration of complete protection against a lethal human infectious disease in nonhuman primates using RNAi, according to lead author Dr. Thomas W. Geisbert of the Boston University School of Medicine.
"We believe this work justifies the immediate development of Ebola SNALP as a countermeasure to treat Ebola infected patients, either in outbreaks or accidental laboratory exposures," he said.
Ebola virus causes hemorrhagic fever with case fatality rates as high as 80 percent in humans. The virus, which is infectious by aerosol (although more commonly spread through blood and bodily fluids of infected patients), is of concern both as a global health threat and a potential agent of biological warfare or terrorism.
Currently there are no available vaccines or therapies, so researchers working with Ebola virus must do so in maximum containment (Biosafety Level 4) laboratories. In these specially designed laboratories, investigators wear positive pressure "space suits" and breathe filtered air as they work, and all laboratory waste streams are sterilized.
The SNALP-RNAi therapeutic used in the study was developed by Tekmira Pharmaceuticals Corporation of Vancouver, BC. Previous research showed that these siRNAs completely protected guinea pigs when administered shortly after a lethal dose of ZEBOV was administered. While rodent studies are useful for screening prospective medical countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models.
Further studies in monkeys would be necessary to refine dosing, toxicology and other issued before the treatment could be licensed for human use.
"The significance of this report goes beyond the protection against Ebola virus," said COL John P. Skvorak, commander of USAMRIID. "It also represents the potential for this concept to be applied to other viral infections."
The study was a collaborative effort between USAMRIID, Boston University and Tekmira, and was partly funded by the Defense Threat Reduction Agency's Transformational Medical Technologies Initiative.
USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Department of Defense Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute conducts basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. While USAMRIID's primary mission is focused on the military, its research often has applications that benefit society as a whole. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command. For more information, visit www.usamriid.army.mil.
Reference: Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Thomas W. Geisbert, Amy C. H. Lee, Marjorie Robbins, Joan B. Geisbert, Anna N. Honko, Vandana Sood, Joshua C. Johnson, Susan de Jong, Iran Tavakoli, Adam Judge, Lisa E. Hensley, Ian MacLachlan. The Lancet: 29 May 2010; 375: 1896-190
Caree Vander Linden | EurekAlert!
Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz
Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB
More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.
Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...
Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.
"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...
The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.
Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...
The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...
Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.
Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...
28.04.2017 | Event News
20.04.2017 | Event News
18.04.2017 | Event News
28.04.2017 | Medical Engineering
28.04.2017 | Earth Sciences
28.04.2017 | Life Sciences